Triple Complex UT Tonic
- Manufacturer
- Feelgood Health | W. Last
- Effective date
- 2010-09-02
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 2
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:35
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
Relieves burning sensation, frequent urination and urgency
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy for prevention of and relief from common bladder problems.
DOSAGE & ADMINISTRATION SECTION
Dosage: Babies and children: Crush 1-2 tablets and sprinkle on tongue 3-6 times daily depending on need. Adults: Dissolve 2-4 tablets in the mouth 3-6 times daily. Maintenance dose: Repeat above dose 2-3 times daily. May be used with BladderWell .
GENERAL PRECAUTIONS SECTION
Dosage: Babies and children: Crush 1-2 tablets and sprinkle on tongue 3-6 times daily depending on need. Adults: Dissolve 2-4 tablets in the mouth 3-6 times daily. Maintenance dose: Repeat above dose 2-3 times daily. May be used with BladderWell .
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of biochemic tissue salts: Ferrum phos (6X) (HPUS), Nat phos (6X) (HPUS), Kali sulph (6X) (HPUS)
INACTIVE INGREDIENT SECTION
Lactose (inactive ingredient).
PREGNANCY SECTION
If pregnant or breastfeeding, ask a health professional before use.
WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives. Safe for all ages and during pregnancy.
INFORMATION FOR PATIENTS SECTION
All Native Remedies health products are especially
formulated by experts in the field of natural health and are manufactured
according to the highest pharmaceutical standards for maximum safety and
effectiveness. For more information, visit us at
www.nativeremedies.com
Distributed by
Native Remedies, LLC
6531 Park of Commerce Blvd.
Suite 160
Boca Raton, FL 33487
Phone: 1.877.289.1235
International: + 1.561.999.8857
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medicines from the reach of children.
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68647-133-10 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-97c3-f424-e053-dadaa90a57ce | TRIPLE COMPLEX UT TONIC |
| 68647-133-60 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-97c3-f424-e053-dadaa90a57ce | TRIPLE COMPLEX UT TONIC |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-133-10 | Triple Complex UT Tonic | 125 in 1 BOTTLE, GLASS | TABLET | 125 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| FERRUM PHOSPHORICUM | ACTIVE INGREDIENT | 91GQH8I5F7 | 2 | |
| POTASSIUM SULFATE | ACTIVE INGREDIENT | 1K573LC5TV | 2 | |
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | ACTIVE INGREDIENT | 22ADO53M6F | 2 | |
| FERRUM PHOSPHORICUM | ACTIVE MOIETY | 91GQH8I5F7 | 2 | |
| POTASSIUM CATION | ACTIVE MOIETY | 295O53K152 | 2 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 2 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 2 |
Products#
Every source-derived product name is available through these pages.
- Triple Complex UT Tonic
- Ferrum phos , Nat phos, Kali sulph
- FERRUM PHOSPHORICUM
- SODIUM PHOSPHATE, DIBASIC ANHYDROUS
- SODIUM CATION
- POTASSIUM SULFATE
- POTASSIUM CATION
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-133 | 68647-133-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| FERRUM PHOSPHORICUM | 91GQH8I5F7 | ACTIB |
| SODIUM PHOSPHATE, DIBASIC ANHYDROUS | 22ADO53M6F | ACTIB |
| POTASSIUM SULFATE | 1K573LC5TV | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f3218b3e-aba5-41d8-a816-d582483af048 | 45228646-e25a-42c1-9288-b3213dd72dce | 2010-09-02 | Warnings | 45228646-e25a-42c1-9288-b3213dd72dce |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
